Inflammatory Profiles of Children at High Risk for Atherosclerosis
The purpose of this study is to evaluate levels of inflammatory mediators in children at risk for cardiovascular disease due to family history. We are measuring inflammatory markers in two groups of children and their parents: children with a family history of early atherosclerotic heart disease (cases), and healthy children without such a family history (controls). The design is a cross-sectional study, gathering a fasting blood sample and clinical and behavioral data on children and a parent.
Metabolic Syndrome X
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Inflammatory Profiles of Children at High Risk for Atherosclerosis|
Fasting serum samples, frozen.
|Study Start Date:||July 2004|
|Study Completion Date:||March 2007|
|Primary Completion Date:||October 2006 (Final data collection date for primary outcome measure)|
Children without family history of early atherosclerosis
Children with family history of early atherosclerosis.
Parents of children without family history of early atherosclerosis
Parents of children with family history of early atherosclerosis
Family history is a well known risk factor for early atherosclerosis. Whether inflammation plays a role in the increased risk of family history is not known. In this prospective single-center study, we are recruiting children with and without a family history of premature atherosclerotic disease, defined as occurring < 55 years in males and <65 years in females. Children are recruited primarily from a pediatric preventive cardiology clinic at Children's Hospital Boston. We measure anthropomorphic characteristics, fasting lipid profiles and inflammatory marker levels, including high sensitivity C-reactive protein (hsCRP), intracellular adhesion molecule 1 (ICAM-1), P-selectin, and tumor necrosis factor alpha receptor 2 (TNFαR2).
In this sample of high-risk overweight children, Lp(a) and inflammatory markers could reflect cardiovascular risk outside lipid profiles.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00115232
|United States, Massachusetts|
|Children's Hospital Boston|
|Boston, Massachusetts, United States, 02115|
|Principal Investigator:||Sarah D. de Ferranti, MD MPH||Children's Hospital Boston|